Promise of Urinary Nerve Growth Factor for Assessment of Overactive XXXX .

@entity1 @entity1494 @entity2336 @entity2182 @entity2335
@entity2182 ( @entity2182 ) is highly prevalent @entity1494 in @entity1 and @entity1 . About 10-15% of the population suffers from urgency frequency with or without urgency urinary incontinence. It is estimated that 50-75% of @entity1 with @entity2182 may have urodynamic detrusor overactivity (DO). Urodynamic study invasive and most of the @entity2182 @entity1 might not accept it as a routine assessment. Therefore, a more objective and non-invasive test for diagnosis and assessing DO from @entity2182 @entity1 is needed. Recently, urinary nerve growth factor (NGF) has gained great interest in detecting DO in @entity1 with @entity2182 . Urinary NGF level was found to increase in @entity2182 and urodynamic DO. Urinary NGF levels correlated with severity of @entity2182 symptoms. @entity1 with either @entity2182 may have increased urinary NGF levels. Urinary NGF levels have been shown to decrease in @entity1 with @entity1 with @entity2182 and DO who have been well treated with antimuscarinics or botulinum toxin injection, but not in those with persistent @entity2182 after treatment. Not all @entity1 with @entity2182 can have an elevated urinary NGF level; it may also be increased in @entity1 with @entity2335 / @entity2336 and other lower urinary tract diseases, suggesting urinary NGF expression could be a product of @entity1494 and a limited specificity of urinary NGF for diagnosing DO. The source of urinary NGF has not yet been fully explored yet. Nevertheless, urinary NGF level is likely to be a promising biomarker for diagnosis of DO from @entity2182 @entity1 , to monitor therapeutic outcome and predict disease progression.
